Diffuse large B-cell lymphoma in adults aged 75 years and older: A single institution analysis of cause-specific survival and prognostic factors

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Background: Very elderly patients (75 years and older) with diffuse large B-cell lymphoma (DLBCL) will be increasingly considered for cancer treatment as the population ages, but are underrepresented in clinical trials. Here we report outcomes of very elderly DLBCL patients treated in the modern era at the Oregon Health and Science University (OHSU). Methods: We queried the OHSU Tumor Registry for DLBCL cases treated since 2002. A total of 73 patients aged 75 years or older were analyzed under Institutional Review Board approval. Results: With a median follow up of 31 months, cause-specific survival was 58% and overall survival 51% at 3 years. Incorporation of an anthracycline did not influence outcomes. More than one extranodal site or poor-risk disease by Revised International Prognostic Index score were adversely prognostic, but pathologic features studied were not. Very elderly patients with DLBCL require prospective studies, which employ novel risk stratification and therapeutic approaches.

Original languageEnglish (US)
Pages (from-to)349-353
Number of pages5
JournalTherapeutic Advances in Hematology
Volume4
Issue number6
DOIs
StatePublished - 2013

Fingerprint

Lymphoma, Large B-Cell, Diffuse
Survival
Research Ethics Committees
Anthracyclines
Health
Registries
Neoplasms
Clinical Trials
Prospective Studies
Therapeutics
Population

Keywords

  • DLBCL
  • elderly
  • prognosis

ASJC Scopus subject areas

  • Hematology

Cite this

@article{2910bed3bc054b7fb759e06bfb2653b5,
title = "Diffuse large B-cell lymphoma in adults aged 75 years and older: A single institution analysis of cause-specific survival and prognostic factors",
abstract = "Background: Very elderly patients (75 years and older) with diffuse large B-cell lymphoma (DLBCL) will be increasingly considered for cancer treatment as the population ages, but are underrepresented in clinical trials. Here we report outcomes of very elderly DLBCL patients treated in the modern era at the Oregon Health and Science University (OHSU). Methods: We queried the OHSU Tumor Registry for DLBCL cases treated since 2002. A total of 73 patients aged 75 years or older were analyzed under Institutional Review Board approval. Results: With a median follow up of 31 months, cause-specific survival was 58{\%} and overall survival 51{\%} at 3 years. Incorporation of an anthracycline did not influence outcomes. More than one extranodal site or poor-risk disease by Revised International Prognostic Index score were adversely prognostic, but pathologic features studied were not. Very elderly patients with DLBCL require prospective studies, which employ novel risk stratification and therapeutic approaches.",
keywords = "DLBCL, elderly, prognosis",
author = "Smith, {Stephen D.} and Andy Chen and Stephen Spurgeon and Craig Okada and Guang Fan and Jennifer Dunlap and Rita Braziel and Richard Maziarz",
year = "2013",
doi = "10.1177/2040620713505048",
language = "English (US)",
volume = "4",
pages = "349--353",
journal = "Therapeutic Advances in Hematology",
issn = "2040-6207",
publisher = "Sage Publications",
number = "6",

}

TY - JOUR

T1 - Diffuse large B-cell lymphoma in adults aged 75 years and older

T2 - A single institution analysis of cause-specific survival and prognostic factors

AU - Smith, Stephen D.

AU - Chen, Andy

AU - Spurgeon, Stephen

AU - Okada, Craig

AU - Fan, Guang

AU - Dunlap, Jennifer

AU - Braziel, Rita

AU - Maziarz, Richard

PY - 2013

Y1 - 2013

N2 - Background: Very elderly patients (75 years and older) with diffuse large B-cell lymphoma (DLBCL) will be increasingly considered for cancer treatment as the population ages, but are underrepresented in clinical trials. Here we report outcomes of very elderly DLBCL patients treated in the modern era at the Oregon Health and Science University (OHSU). Methods: We queried the OHSU Tumor Registry for DLBCL cases treated since 2002. A total of 73 patients aged 75 years or older were analyzed under Institutional Review Board approval. Results: With a median follow up of 31 months, cause-specific survival was 58% and overall survival 51% at 3 years. Incorporation of an anthracycline did not influence outcomes. More than one extranodal site or poor-risk disease by Revised International Prognostic Index score were adversely prognostic, but pathologic features studied were not. Very elderly patients with DLBCL require prospective studies, which employ novel risk stratification and therapeutic approaches.

AB - Background: Very elderly patients (75 years and older) with diffuse large B-cell lymphoma (DLBCL) will be increasingly considered for cancer treatment as the population ages, but are underrepresented in clinical trials. Here we report outcomes of very elderly DLBCL patients treated in the modern era at the Oregon Health and Science University (OHSU). Methods: We queried the OHSU Tumor Registry for DLBCL cases treated since 2002. A total of 73 patients aged 75 years or older were analyzed under Institutional Review Board approval. Results: With a median follow up of 31 months, cause-specific survival was 58% and overall survival 51% at 3 years. Incorporation of an anthracycline did not influence outcomes. More than one extranodal site or poor-risk disease by Revised International Prognostic Index score were adversely prognostic, but pathologic features studied were not. Very elderly patients with DLBCL require prospective studies, which employ novel risk stratification and therapeutic approaches.

KW - DLBCL

KW - elderly

KW - prognosis

UR - http://www.scopus.com/inward/record.url?scp=84993725188&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84993725188&partnerID=8YFLogxK

U2 - 10.1177/2040620713505048

DO - 10.1177/2040620713505048

M3 - Article

AN - SCOPUS:84993725188

VL - 4

SP - 349

EP - 353

JO - Therapeutic Advances in Hematology

JF - Therapeutic Advances in Hematology

SN - 2040-6207

IS - 6

ER -